Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cells

Tumori

Volumn 87, Issue 3, 2001, Pages 134-137

  Tartarone, A ^a   Sirotova Z ^a   Aieta, M ^a   Lelli, G ^a  

^a Division of Oncology   (Italy)

Author keywords

Breast cancer; Epirubicin; High dose chemotherapy; Paclitaxel; Salvage treatment

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; ORPHENADRINE; PACLITAXEL; PREDNISONE; RANITIDINE; THIOTEPA; VINCRISTINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0034934535     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700305     Document Type: Article

References (22)

1. High dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
2. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results
3. High dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: A 10-year experience
4. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
5. The MD Anderson Cancer Center experience with taxol in metastatic breast cancer
6. First-line treatment of metastatic breast cancer
7. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
8. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
9. Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
10. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
11. Phase I studies of combined paclitaxel/epirubicin/ and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic breast cancer: The French experience
12. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
13. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
14. Nonparametric estimation from incomplete observations
15. Paclitaxel activity in heavily pretreated breast cancer: The National Cancer Institute Treatment Referral Center trial
16. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
17. High dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: Hematopoietic tolerance and efficacy
18. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial
19. Metastatic breast cancer: The role of chemotherapy
20. Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer
21. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy